Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer

Fig. 3

Anti-TNBC efficacy and host toxicity of Nano-DOX in comparison with DOX. a Peripheral blood smears from 4T1-tumor bearing mice at the end of 3-week treatment of Nano-DOX or DOX. b Spleen size and spleen index of 4T1-tumor bearing mice at the end of 3-week treatment of Nano-DOX or DOX. c H&E staining of spleen tissues from 4T1-tumor bearing mice at the end of 3-week treatment of Nano-DOX or DOX. d Immunohistochemical staining of CD3 (marker of lymphocytes) and F4/80 (marker of macrophages) in spleen tissues from 4T1-tumor bearing mice at the end of 3-week treatment of Nano-DOX or DOX. e Effects of Nano-DOX and DOX on the viability of bone marrow-derived dendritic cells (BMDC), lymphocytes (LC), bone marrow-derived macrophages (BMDM) and myeloid-derived suppressor cells (MDSCs) assayed by CCK-8 test. f Body weight (b.w.) changes of 4T1-tumor bearing mice at the end of 3-week treatment of Nano-DOX or DOX. Duration of Nano-DOX or DOX treatment was 24 h for the ex vivo cell experiments. Values were mean ± SD (n = 5 for in vitro experiments and n = 8 for in vivo experiments, *p < 0.05, **p < 0.01)

Back to article page